Equities

Biogen Inc

0R1B:LSE

Biogen Inc

  • Price (USD)229.33
  • Today's Change0.00 / 0.00%
  • Shares traded3.01k
  • 1 Year change-24.31%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 19:05 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Biogen Inc's revenues fell -3.32% from 10.17bn to 9.84bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 3.05bn to 1.16bn, a -61.89% decrease.
Gross margin75.03%
Net profit margin12.08%
Operating margin17.21%
Return on assets4.56%
Return on equity8.04%
Return on investment5.20%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Biogen Inc fell by 2.37bn. However, the company earned 1.55bn from its operations for a Cash Flow Margin of 15.73%. In addition the company generated 149.30m cash from financing while 4.10bn was spent on investing.
Cash flow per share11.66
Price/Cash flow per share19.78
Book value per share104.48
Tangible book value per share4.81
More ▼

Balance sheet in USDView more

Biogen Inc has a Debt to Total Capital ratio of 30.07%, a lower figure than the previous year's 45.54%.
Current ratio2.10
Quick ratio1.32
Total debt/total equity0.4299
Total debt/total capital0.3007
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-18.14
EPS (TTM) vs
TTM 1 year ago		-62.83
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.